Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study
Dupilumab treatment was associated with lower all-cause mortality among patients with asthma, despite increased risk of lymphoma, particularly T-cell and NK-cell lymphomas. These findings highlight the need for long-term surveillance and further research into the immunological mechanisms underlying dupilumab-associated lymphoma in asthma.
Authors
- Steven T. Chen
- Joseph Ebriani
- Allison Holt (ORCID: https://orcid.org/0009-0008-1269-1255)
- Mike Westmeijer (ORCID: https://orcid.org/0000-0002-2896-9994)
- Wanda Phipatanakul (ORCID: https://orcid.org/0000-0001-8639-0473)
- Serena Yun‐Chen Tsai (ORCID: https://orcid.org/0000-0002-5778-645X)
- Rebecca R. Saff (ORCID: https://orcid.org/0000-0002-4143-0985)
- Carlos A. Camargo (ORCID: https://orcid.org/0000-0002-5071-7654)
- Bethany Brumbaugh (ORCID: https://orcid.org/0009-0004-8176-9707)
- Kevin Sheng-Kai
Institutions
- Boston Children's Hospital (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Center for Global Health (US)
- Institut de Recherche sur les Phénomènes Hors Équilibre (FR)
- University of Pennsylvania (US)
- Saft (France) (FR)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1183/13993003.00139-2025
- Citations
- 16
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 32.08